Components of survival time of screen detected cancer cases
Principal Investigator
Name
Philip Prorok
Institution
NCI
Position Title
Scientific Program Manager
Email
About this CDAS Project
Study
PLCO
(Learn more about this study)
Project ID
PLCO-129
Initial CDAS Request Approval
Feb 3, 2015
Title
Components of survival time of screen detected cancer cases
Summary
The goal of this project is to estimate the mean duration of the components of the survival time of individuals who are diagnosed with screen detected cancer. The fact that the numbers of cases in the arms of a randomized screening trial are equal on average in the absence of screening is exploited. Using mean lead time from standard approaches and the number of cases in each arm yields the mean preclinical duration and the mean benefit time. Four settings are considered – benefit yes, no and overdiagnosis yes, no. Data to address these four settings are requested from the following trials: NLST, PLCO-O, PLCO-L, HIP, Mayo Clinic, Johns Hopkins Lung Project and Memorial Sloan-Kettering. Required data elements include identifier, cohort (screened, refused, control), times from entry to diagnosis, entry to death, and diagnosis to death, mode of detection, and cause of death.
Aims
Estimation of the preclinical sojourn time and benefit time of screen detected cancer cases both with and without overdiagnosis.
Collaborators
Karen Kafadar - University of Virginia